Innovative Neuroscience Company Shows at RESI Challenge
BOSTON, September 13, 2016 – Novoron Bioscience took home 3rd Prize in the 2016 Redefining Early Stage Investments (RESI) Innovation Challenge. Novoron was one of 30 life sciences companies to compete in the challenge, which included enterprises in the Therapeutics, Medical Devices, Diagnostics, Technology Platform and Digital Health categories. Novoron is developing first-in-class neuroregenerative treatments for conditions of the central nervous system and is currently focused on multiple sclerosis (MS) and spinal cord injury therapeutics.
Novoron CEO and President, Dr. Travis Stiles commented, "Finishing as well as we did in the RESI challenge in the company of so many other incredibly innovative companies is an honor. We feel really good about our momentum going into 2017."
